Compounds > beta-alanine
Page last updated: 2024-10-16

beta-alanine and Thromboembolism

beta-alanine has been researched along with Thromboembolism in 144 studies

Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.

Research Excerpts

ExcerptRelevanceReference
"In a retrospective pilot trial comparing the risks of systemic thromboembolism or bleeding complications in patients treated with warfarin or dabigatran anticoagulation, the outcomes were similar."9.17Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. ( Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E, 2013)
"Periprocedural anticoagulation using uninterrupted warfarin could reduce the risk of thromboembolic complications of atrial fibrillation (AF) ablation."9.16Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. ( Fuke, E; Hayano, M; Kaseno, K; Kumagai, K; Miki, Y; Naito, S; Nakamura, K; Nishiuchi, S; Oshima, S; Sakamoto, T; Sasaki, T; Tada, H; Tsukada, N; Yamashita, E, 2012)
"Dabigatran and warfarin were associated with similar rates of periprocedural bleeding, including patients having urgent surgery."9.16Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012)
"To evaluate the prognostic importance of CHADS(2) risk score in patients with atrial fibrillation receiving oral anticoagulants, including the vitamin K antagonist warfarin and the direct thrombin inhibitor dabigatran."9.15Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. ( Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2011)
"Dabigatran etexilate, a new thrombin inhibitor, has been shown to be comparable to warfarin in patients with atrial fibrillation (AF)."8.90Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. ( Albenque, JP; Bouzeman, A; Boveda, S; Casteigt, B; Combes, N; Combes, S; Marijon, E; Narayanan, K; Providência, R, 2014)
"Several studies have been conducted to study the efficacy and safety of rivaroxaban in the atrial fibrillation periprocedural ablation period with similar rates of thromboembolism and major bleeding risks compared with warfarin or dabigatran."8.90Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. ( Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A, 2014)
"Dabigatran is a novel oral anticoagulant and may be useful during atrial fibrillation (AF) ablation for prevention of thromboembolic events."8.90Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. ( Aronow, WS; Chatterjee, S; Ghosh, J; Nairooz, R; Sardar, P; Wetterslev, J, 2014)
"Dabigatran is approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF)."8.89Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. ( Alexander, JH; Atwater, BD; Bahnson, TD; Daubert, JP; Hasselblad, V; Piccini, JP; Steinberg, BA; Washam, JB, 2013)
"For several decades now, oral anticoagulation with warfarin has represented the cornerstone of measures to prevent occurrence of ischemic stroke in high-risk patients with atrial fibrillation."8.87Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. ( Acharjee, S; Cannon, CP, 2011)
" We present a case in which a patient abruptly stopped taking dabigatran due to a small bowel obstruction and shortly thereafter suffered a myocardial infarction complicated by left ventricular thrombosis with fatal embolisation to the superior mesenteric artery."7.80Myocardial infarction complicated by left ventricular thrombus and fatal thromboembolism following abrupt cessation of dabigatran. ( Marciniak, ET; McCurdy, MT; Reed, RM; Weiler, B, 2014)
"This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation initiating treatment before age 75 (<75), at or after age 75 (≥ 75), and the overall population (All) from a US Medicare payer perspective."7.80Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. ( Brand, S; Brueckmann, M; Clemens, A; Kansal, A; Lim, J; Noack, H; Peng, S; Sander, S; Sorensen, S, 2014)
" A second woman with primary APS experienced ischemic arterial strokes and right transverse-sigmoid sinus thrombosis after conversion to rivaroxaban."7.80Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. ( Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE, 2014)
"Dabigatran etexilate can safely be used for thromboembolism prophylaxis after primary total hip replacement without an increased risk for perioperative blood loss and prolonged wound secretion."7.80Effects of thromboembolism prophylaxis with dabigatran on perioperative blood loss and wound secretion in primary hip arthroplasty. ( Doering, M; Egidy, C; Gehrke, T; Kendoff, D; Krettek, C; Mommsen, P; R O Hrs, E, 2014)
"It is not clear whether dabigatran is as safe and effective as uninterrupted anticoagulation with warfarin during radiofrequency catheter ablation (RFA) of atrial fibrillation (AF)."7.79Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. ( Bogun, F; Carrigan, T; Chugh, A; Crawford, T; Ghanbari, H; Good, E; Jongnarangsin, K; Kennedy, R; Kim, JS; Latchamsetty, R; Morady, F; Oral, H; Pelosi, F; Saint-Phard, W; She, F; Sinno, M; Suwanagool, A; Yokokawa, M, 2013)
"A 65-year-old man, who had been treated with dabigatran for 66 days prior to electrical cardioversion, developed extensive intestinal, renal and cerebral thromboembolism five days after cardioversion."7.79[Extensive thromboembolism after cardioversion in a patient treated with dabigatran]. ( Buch, TN; Holm, J; Munck, LK, 2013)
"Dabigatran is effective for both the prevention of stroke and bleeding in patients with atrial fibrillation (AF)."7.79Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. ( Fujiwara, R; Fukuzawa, K; Hirata, K; Imamura, K; Itoh, M; Kiuchi, K; Matsumoto, A; Nakanishi, T; Suzuki, A; Takami, K; Takami, M; Takei, A; Yamashita, S; Yoshida, A, 2013)
"The purpose of this study was to evaluate the feasibility and safety of periprocedural dabigatran during atrial fibrillation (AF) ablation."7.78Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. ( Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR, 2012)
"A 20-year-old white male was prescribed oral dabigatran 150 mg twice daily for thromboembolic prevention because of nonvalvular atrial fibrillation."7.77Drug-induced exanthem following dabigatran. ( Blais, DM; Boyd, JM; Hummel, J; Whitehead, H, 2011)
"The central pharmacologic approach to stroke prevention in atrial fibrillation has recently changed with the approval of dabigatran by the US Food and Drug Administration (FDA)."7.77Dabigatran in atrial fibrillation: pharmacology and clinical trials. ( Ezekowitz, MD; Nagarakanti, R, 2011)
" Rywaroxaban more frequently causes minor bleeding, whereas treatment with dabigatran is associated with more frequent gastrointestinal adverse symptoms."6.79[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. ( Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L, 2014)
"Clinical results of the European Action on Anticoagulation (EAA) computer-assisted dosage study and the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial have been compared."6.79Warfarin or dabigatran for treatment of atrial fibrillation. ( Ibrahim, S; Jespersen, J; Poller, L, 2014)
"Dabigatran was associated with a decreased risk of intracranial bleeding (RR 0."6.50Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. ( Atallah, R; Bloom, BJ; Eisenberg, MJ; Filion, KB, 2014)
"Dabigatran is an oral direct thrombin inhibitor."6.48[Clinical studies, the interests and limits of using dabigatran in atrial fibrillation]. ( Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Spinewine, A; Sternotte, A, 2012)
"Rivaroxaban is an oral Xa inhibitor which shows a significantly better efficacy compared to enoxaparin and no difference in side effects."6.46[Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ]. ( Gogarten, W; Pauschert, R; Quante, M, 2010)
"Direct-current cardioversion (DCCV) for persistent atrial fibrillation or atrial flutter (AF) carries a risk of thromboembolic events (TEs)."5.40Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. ( Groh, C; Passman, R; Yadlapati, A, 2014)
"Dabigatran was started 22 hours postablation with drug dose based on renal function."5.38The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012)
"The use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications, as compared with warfarin, thus showing no benefit and an excess risk."5.17Dabigatran versus warfarin in patients with mechanical heart valves. ( Blatchford, J; Brueckmann, M; Connolly, SJ; Devenny, K; Eikelboom, JW; Friedman, J; Granger, CB; Guiver, K; Harper, R; Kappetein, AP; Khder, Y; Lobmeyer, MT; Maas, H; Mack, MJ; Simoons, ML; Van de Werf, F; Voigt, JU, 2013)
"In a retrospective pilot trial comparing the risks of systemic thromboembolism or bleeding complications in patients treated with warfarin or dabigatran anticoagulation, the outcomes were similar."5.17Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. ( Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E, 2013)
"Dabigatran and warfarin were associated with similar rates of periprocedural bleeding, including patients having urgent surgery."5.16Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012)
"Periprocedural anticoagulation using uninterrupted warfarin could reduce the risk of thromboembolic complications of atrial fibrillation (AF) ablation."5.16Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. ( Fuke, E; Hayano, M; Kaseno, K; Kumagai, K; Miki, Y; Naito, S; Nakamura, K; Nishiuchi, S; Oshima, S; Sakamoto, T; Sasaki, T; Tada, H; Tsukada, N; Yamashita, E, 2012)
"To evaluate the prognostic importance of CHADS(2) risk score in patients with atrial fibrillation receiving oral anticoagulants, including the vitamin K antagonist warfarin and the direct thrombin inhibitor dabigatran."5.15Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. ( Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2011)
"Dabigatran is a novel oral anticoagulant and may be useful during atrial fibrillation (AF) ablation for prevention of thromboembolic events."4.90Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. ( Aronow, WS; Chatterjee, S; Ghosh, J; Nairooz, R; Sardar, P; Wetterslev, J, 2014)
"Several studies have been conducted to study the efficacy and safety of rivaroxaban in the atrial fibrillation periprocedural ablation period with similar rates of thromboembolism and major bleeding risks compared with warfarin or dabigatran."4.90Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. ( Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A, 2014)
"Dabigatran etexilate, a new thrombin inhibitor, has been shown to be comparable to warfarin in patients with atrial fibrillation (AF)."4.90Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. ( Albenque, JP; Bouzeman, A; Boveda, S; Casteigt, B; Combes, N; Combes, S; Marijon, E; Narayanan, K; Providência, R, 2014)
"Oral anticoagulant therapy, either with vitamin K antagonists (VKAs) or with novel oral anticoagulants such as dabigatran, rivaroxaban, and apixaban, is the mainstay for thromboprophylaxis in patients with atrial fibrillation (AF)."4.89Anticoagulation management in nonvalvular atrial fibrillation: current and future directions. ( Kornej, J; Lip, GY; Potpara, T, 2013)
"In patients with atrial fibrillation (AF) oral anticoagulation with vitamin-K antagonists (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention yielding a 60-70% relative reduction in stroke risk compared with placebo, as well as a mortality reduction of 26 percent."4.89Novel oral anticoagulants in secondary prevention of stroke. ( Diener, HC; Easton, JD; Hankey, GJ; Hart, RG, 2013)
"Dabigatran is approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF)."4.89Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. ( Alexander, JH; Atwater, BD; Bahnson, TD; Daubert, JP; Hasselblad, V; Piccini, JP; Steinberg, BA; Washam, JB, 2013)
"The oral direct thrombin inhibitor dabigatran effectively prevents arterial and venous thromboembolism using fixed doses without the need for adjustment according to laboratory results."4.88Determination of dabigatran in human plasma samples. ( Giese, C; Harenberg, J; Krämer, R; Marx, S, 2012)
" Dabigatran, compared with warfarin, was associated with lower rates of stroke or thromboembolism and systemic embolism but similar rates of major haemorrhage and death."4.88Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison. ( Alonso-Coello, P; Guyatt, G; Zhou, Q, 2012)
"The original RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy) trial suggested a small increased risk of myocardial infarction (MI) with the use of dabigatran etexilate vs warfarin in patients with atrial fibrillation."4.88Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. ( Hernandez, AV; Uchino, K, 2012)
"For several decades now, oral anticoagulation with warfarin has represented the cornerstone of measures to prevent occurrence of ischemic stroke in high-risk patients with atrial fibrillation."4.87Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. ( Acharjee, S; Cannon, CP, 2011)
"Long-term anticoagulation with a vitamin K antagonist (VKA) or the new agent dabigatran is recommended to decrease stroke risk in patients with atrial fibrillation."4.87Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies. ( Garwood, CL; Hwang, JM; Moser, LR, 2011)
"Warfarin has been the effective treatment in the prophylaxis of cardioembolism, in particular in patients with atrial fibrillation, for more than 50 years."4.87[Thromboembolic prophylaxis 2011: is warfarin on the wane?]. ( Di Pasquale, G; Riva, L, 2011)
"In the RE-LY trial dabigatran 150 mg twice daily (D150) showed significantly fewer strokes, and 110 mg (D110) significantly fewer major bleeding events (MBE) compared to well-controlled warfarin in patients with atrial fibrillation (AF)."3.80Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. ( Clemens, A; Connolly, SJ; Ferreira, J; Lip, GY; Noack, H; Yusuf, S, 2014)
" Therefore, we compared the incidence of bleeding and thrombo-embolic complications following cardiac rhythm device (CRD) implantations under dabigatran vs."3.80Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations. ( Bollmann, A; Breithardt, OA; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P, 2014)
" We present a case in which a patient abruptly stopped taking dabigatran due to a small bowel obstruction and shortly thereafter suffered a myocardial infarction complicated by left ventricular thrombosis with fatal embolisation to the superior mesenteric artery."3.80Myocardial infarction complicated by left ventricular thrombus and fatal thromboembolism following abrupt cessation of dabigatran. ( Marciniak, ET; McCurdy, MT; Reed, RM; Weiler, B, 2014)
" A second woman with primary APS experienced ischemic arterial strokes and right transverse-sigmoid sinus thrombosis after conversion to rivaroxaban."3.80Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. ( Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE, 2014)
" A direct thrombin inhibitor, dabigatran etexilate (hereinafter referred to as dabigatran) was approved in the Russian Federation for prevention of thromboembolic complications in orthopaedic practice (2009), for prevention of ischaemic embologenic stroke in atrial fibrillation (2011) and for treatment of recurrent thrombosis of deep veins and pulmonary artery thromboembolism (2014)."3.80[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor]. ( Beliavskaia, OO; Vavilova, TV, 2014)
"Dabigatran etexilate can safely be used for thromboembolism prophylaxis after primary total hip replacement without an increased risk for perioperative blood loss and prolonged wound secretion."3.80Effects of thromboembolism prophylaxis with dabigatran on perioperative blood loss and wound secretion in primary hip arthroplasty. ( Doering, M; Egidy, C; Gehrke, T; Kendoff, D; Krettek, C; Mommsen, P; R O Hrs, E, 2014)
"The new oral anticoagulants (NOAC), dabigatran and rivaroxaban, have been demonstrated to be at least equivalent to warfarin for preventing cardiac thromboembolism (TE) in patients with atrial fibrillation (AF)."3.80Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. ( Badhwar, N; Gerstenfeld, EP; Lee, BK; Lee, RJ; Marcus, GM; Olgin, J; Scheinman, M; Stepanyan, G; Tseng, ZH; Vedantham, V, 2014)
"This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation initiating treatment before age 75 (<75), at or after age 75 (≥ 75), and the overall population (All) from a US Medicare payer perspective."3.80Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. ( Brand, S; Brueckmann, M; Clemens, A; Kansal, A; Lim, J; Noack, H; Peng, S; Sander, S; Sorensen, S, 2014)
"To reverse the anticoagulant effects of warfarin in patients who are bleeding or need surgery, exogenous vitamin K (phytonadione) may be used in combination with another, shorter-acting intervention, such as fresh frozen plasma (FFP), prothrombin complex concentrate (PCC), recombinant factor VIIa, or activated PCC (aPCC)."3.79Pharmacologic interventions for reversing the effects of oral anticoagulants. ( Kalus, JS, 2013)
"Dabigatran is effective for both the prevention of stroke and bleeding in patients with atrial fibrillation (AF)."3.79Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. ( Fujiwara, R; Fukuzawa, K; Hirata, K; Imamura, K; Itoh, M; Kiuchi, K; Matsumoto, A; Nakanishi, T; Suzuki, A; Takami, K; Takami, M; Takei, A; Yamashita, S; Yoshida, A, 2013)
"A 65-year-old man, who had been treated with dabigatran for 66 days prior to electrical cardioversion, developed extensive intestinal, renal and cerebral thromboembolism five days after cardioversion."3.79[Extensive thromboembolism after cardioversion in a patient treated with dabigatran]. ( Buch, TN; Holm, J; Munck, LK, 2013)
"It is not clear whether dabigatran is as safe and effective as uninterrupted anticoagulation with warfarin during radiofrequency catheter ablation (RFA) of atrial fibrillation (AF)."3.79Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. ( Bogun, F; Carrigan, T; Chugh, A; Crawford, T; Ghanbari, H; Good, E; Jongnarangsin, K; Kennedy, R; Kim, JS; Latchamsetty, R; Morady, F; Oral, H; Pelosi, F; Saint-Phard, W; She, F; Sinno, M; Suwanagool, A; Yokokawa, M, 2013)
"The purpose of this study was to evaluate the feasibility and safety of periprocedural dabigatran during atrial fibrillation (AF) ablation."3.78Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. ( Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR, 2012)
"On October 19, 2010, the Food and Drug Administration approved dabigatran (Pradaxa) for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF)."3.78Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin? ( Freeman, MK; Hughes, PJ, 2012)
"Dabigatran has been rapidly adopted into ambulatory practice in the United States, primarily for treatment of atrial fibrillation, but increasingly for off-label indications."3.78National trends in oral anticoagulant use in the United States, 2007 to 2011. ( Alexander, GC; Kirley, K; Kornfield, R; Qato, DM; Stafford, RS, 2012)
"We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age."3.78[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. ( Kanorsky, SG; Shevelev, VI, 2012)
"A 20-year-old white male was prescribed oral dabigatran 150 mg twice daily for thromboembolic prevention because of nonvalvular atrial fibrillation."3.77Drug-induced exanthem following dabigatran. ( Blais, DM; Boyd, JM; Hummel, J; Whitehead, H, 2011)
"The central pharmacologic approach to stroke prevention in atrial fibrillation has recently changed with the approval of dabigatran by the US Food and Drug Administration (FDA)."3.77Dabigatran in atrial fibrillation: pharmacology and clinical trials. ( Ezekowitz, MD; Nagarakanti, R, 2011)
" Rywaroxaban more frequently causes minor bleeding, whereas treatment with dabigatran is associated with more frequent gastrointestinal adverse symptoms."2.79[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. ( Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L, 2014)
"Clinical results of the European Action on Anticoagulation (EAA) computer-assisted dosage study and the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial have been compared."2.79Warfarin or dabigatran for treatment of atrial fibrillation. ( Ibrahim, S; Jespersen, J; Poller, L, 2014)
"Dabigatran was associated with a decreased risk of intracranial bleeding (RR 0."2.50Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. ( Atallah, R; Bloom, BJ; Eisenberg, MJ; Filion, KB, 2014)
"Stroke is a common disease, which is associated with high morbidity and high mortality."2.49[Anticoagulant therapy in stroke patients]. ( Grove, EL; Husted, SE; Kraglund, KL; Modrau, B, 2013)
"Dabigatran is a reversible, direct thrombin inhibitor, which is administered as dabigatran etexilate, the oral prodrug."2.48New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. ( Dahl, OE, 2012)
"Dabigatran is a potent reversible, competitive direct thrombin inhibitor which is available as the prodrug, Dabigatran etexilate."2.48Dabigatran: a new chapter in anticoagulation. ( Ahmed, S; Levin, V; Malacoff, R; Martinez, MW, 2012)
" Experience with long-term use (> 5 years) is limited."2.48[Clinical pharmacological aspects of new oral anticoagulants]. ( Haschke, M, 2012)
"Dabigatran is an oral direct thrombin inhibitor."2.48[Clinical studies, the interests and limits of using dabigatran in atrial fibrillation]. ( Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Spinewine, A; Sternotte, A, 2012)
" These agents promise to be more convenient to administer with fixed dosing but still have equivalent efficacy and improved bleeding risk compared to warfarin."2.48Newer oral anticoagulant agents: a new era in medicine. ( Goel, R; Srivathsan, K, 2012)
"Rivaroxaban is an oral Xa inhibitor which shows a significantly better efficacy compared to enoxaparin and no difference in side effects."2.46[Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ]. ( Gogarten, W; Pauschert, R; Quante, M, 2010)
" The objective of the study was to validate a dosing regimen for use of dabigatran in patients with mechanical heart valves."1.40Dabigatran use in mechanical heart valve patients. ( Pai, RG; Tafreshi, J; Zough, F, 2014)
"Direct-current cardioversion (DCCV) for persistent atrial fibrillation or atrial flutter (AF) carries a risk of thromboembolic events (TEs)."1.40Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. ( Groh, C; Passman, R; Yadlapati, A, 2014)
"Dabigatran was started 22 hours postablation with drug dose based on renal function."1.38The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012)
"Rivaroxaban however has been granted authorisation by the FDA for the thromboprophylaxis after surgery for total hip or knee surgery."1.37[Pharmacologic heterogeneity of new anticoagulants]. ( Combe, S; Conard, J; Flaujac, C; Horellou, MH; Samamaa, MM, 2011)

Research

Studies (144)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's144 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Buch, TN1
Holm, J1
Munck, LK1
Kasmeridis, C1
Lip, GY4
Apostolakis, S1
David, JS1
Piriou, V1
Albaladejo, P1
Hjemdahl, P1
Johnsson, H1
Wallén, NH1
Bassiouny, M2
Saliba, W2
Rickard, J2
Shao, M2
Sey, A2
Diab, M2
Martin, DO2
Hussein, A2
Khoury, M2
Abi-Saleh, B2
Alam, S2
Sengupta, J2
Borek, PP2
Baranowski, B2
Niebauer, M2
Callahan, T2
Varma, N2
Chung, M2
Tchou, PJ2
Kanj, M2
Dresing, T2
Lindsay, BD2
Wazni, O2
Stiefelhagen, P1
Imamura, K1
Yoshida, A1
Takei, A1
Fukuzawa, K1
Kiuchi, K1
Takami, K1
Takami, M1
Itoh, M1
Fujiwara, R1
Suzuki, A1
Nakanishi, T1
Yamashita, S1
Matsumoto, A1
Hirata, K1
McKenzie, JL1
Douglas, G1
Bazargan, A1
Nutescu, EA1
Kalus, JS1
Healey, JS2
Eikelboom, J3
Yang, S3
Themeles, E2
Connolly, SJ5
Yusuf, S4
Douketis, J3
Wallentin, L3
Oldgren, J3
Heidbuchel, H2
Avezum, A2
Reilly, P2
Ezekowitz, M2
Bauer, KA1
Klein, HH1
Haines, DE1
Mead-Salley, M1
Salazar, M1
Marchlinski, FE1
Zado, E1
Calkins, H2
Yarmohammadi, H1
Nademanee, K1
Amnueypol, M1
Skanes, AC1
Saklani, P1
Hamidi, V1
Ringerike, T1
Hagen, G1
Reikvam, Å1
Klemp, M1
Liew, A1
Ferrandis, R1
Castillo, J1
de Andrés, J1
Gomar, C1
Gómez-Luque, A1
Hidalgo, F1
Llau, JV1
Sierra, P1
Torres, LM1
Providência, R3
Albenque, JP3
Combes, S2
Bouzeman, A1
Casteigt, B1
Combes, N2
Narayanan, K1
Marijon, E3
Boveda, S3
Atar, S1
Wishniak, A1
Shturman, A1
Shtiwi, S1
Brezins, M1
Steinberg, BA1
Hasselblad, V1
Atwater, BD1
Bahnson, TD1
Washam, JB1
Alexander, JH1
Daubert, JP1
Piccini, JP1
Noheria, A1
Asirvatham, SJ1
May, MA1
Gruel, Y1
Fauchier, L1
Potpara, TS1
Bennaghmouch, N1
Ten Berg, JM1
Diener, HC2
Easton, JD1
Hankey, GJ1
Hart, RG1
Majeed, A1
Schulman, S4
Hylek, EM1
Eikelboom, JW4
Brueckmann, M4
Granger, CB2
Kappetein, AP1
Mack, MJ1
Blatchford, J1
Devenny, K1
Friedman, J1
Guiver, K1
Harper, R1
Khder, Y1
Lobmeyer, MT1
Maas, H1
Voigt, JU1
Simoons, ML1
Van de Werf, F3
Roberts, A1
Kornej, J1
Potpara, T1
Bin Abdulhak, AA2
Khan, AR2
Tleyjeh, IM1
Wimmer, AP2
Clemens, A2
Noack, H2
Ferreira, J1
Kolias, TJ1
Zough, F1
Tafreshi, J1
Pai, RG1
Christensen, TD1
Larsen, TB1
Bloom, BJ1
Filion, KB1
Atallah, R1
Eisenberg, MJ1
Sharma, S1
Singh, S1
Stratta, P1
Battista, M1
Guglielmetti, G1
Gasparovic, H1
Petricevic, M1
Biocina, B1
Speirs, A1
Deakin, A1
Chin, PK1
Wright, DF1
Begg, EJ1
Stewart, RA1
Kosiuk, J1
Koutalas, E1
Doering, M2
Sommer, P1
Rolf, S1
Breithardt, OA1
Nedios, S1
Dinov, B1
Hindricks, G1
Richter, S1
Bollmann, A1
Sardar, P2
Nairooz, R2
Chatterjee, S2
Wetterslev, J1
Ghosh, J1
Aronow, WS1
Molinier, A1
Acket, B1
Bourrel, R1
Lavezzi, O1
Montastruc, JL1
Bagheri, H1
Jourda, F1
Hireche, H1
Morais, J1
Yau, JW1
Liao, P1
Fredenburgh, JC1
Roberts, RS1
Weitz, JI3
Yadlapati, A1
Groh, C1
Passman, R1
Stepanyan, G1
Badhwar, N1
Lee, RJ1
Marcus, GM1
Lee, BK1
Tseng, ZH1
Vedantham, V1
Olgin, J1
Scheinman, M1
Gerstenfeld, EP2
Fenger-Eriksen, C1
Münster, AM1
Grove, EL2
Gallus, A1
Poller, L1
Jespersen, J1
Ibrahim, S1
Steurer, J2
Dempfle, CE1
Fernández de Velasco Pérez, D1
Aryal, MR1
Ukaigwe, A1
Pandit, A1
Karmacharya, P1
Pradhan, R1
Mainali, NR1
Pathak, R1
Jalota, L1
Bhandari, Y1
Donato, A1
Herzog, E1
Mukherjee, D1
Halperin, JL1
Weiler, B1
Marciniak, ET1
Reed, RM1
McCurdy, MT1
Peng, S1
Brand, S1
Kansal, A1
Lim, J1
Sander, S1
Sorensen, S1
Winkle, RA2
Mead, RH2
Engel, G2
Kong, MH2
Patrawala, RA2
Schaefer, JK1
McBane, RD1
Black, DF1
Williams, LN1
Moder, KG1
Wysokinski, WE1
Barnes, GD1
Eagle, KA1
Froehlich, JB1
Cutler, TW1
Chuang, A1
Huynh, TD1
Witt, RG1
Branch, J1
Pon, T1
White, R1
Mommsen, P1
R O Hrs, E1
Egidy, C1
Gehrke, T1
Krettek, C1
Kendoff, D1
Ulrich, LR1
Mergenthal, K1
Petersen, JJ1
Roehl, I1
Rauck, S1
Kemperdick, B1
Schulz-Rothe, S1
Berghold, A1
Siebenhofer, A1
Costin, J1
Ansell, J1
Laulicht, B1
Bakhru, S1
Steiner, S1
Schilling, R1
Verma, A1
Willems, S1
Beliavskaia, OO1
Vavilova, TV1
Sengupta, N1
Feuerstein, JD1
Patwardhan, VR1
Tapper, EB1
Ketwaroo, GA1
Thaker, AM1
Leffler, DA1
Gorzelak-Pabiś, P1
Duraj, I1
Szlagowska, L1
Ciastkowska, A1
Broncel, M1
Karetová, D1
Bultas, J1
Liotta, EM1
Levasseur-Franklin, KE1
Naidech, AM1
Oberhofer, E1
Messerschmidt, C1
Friedman, RJ1
Yeh, CH1
Hogg, K1
Park, CI1
Pruvot, E1
Jadidi, A1
Lehrmann, H1
Weber, R1
Arentz, T1
Zimmermann, M1
Gehrie, E1
Tormey, C1
Carrier, M1
Lee, AY1
Shivakumar, S1
Blostein, M1
Spencer, FA1
Solymoss, S1
Barty, R1
Wang, G1
Heddle, N1
Douketis, JD2
Zeus, T1
Kelm, M1
Bode, C2
Quante, M1
Pauschert, R1
Gogarten, W1
Escobar, C1
Barrios, V1
Jimenez, D1
Giorgi, MA1
Cohen Arazi, H1
Gonzalez, CD1
Di Girolamo, G1
Rutzen-Lopez, H1
Khanna, V1
Vkhanna, V1
Reynolds, MR1
Reynolds, M1
Dumont, B1
Faille, D1
Ajzenberg, N1
Ezekowitz, MD2
Nagarakanti, R1
Kazmi, RS1
Lwaleed, BA1
Shin, DI1
Eckardt, L1
Mega, JL1
Averkov, OV1
Whitehead, H1
Boyd, JM1
Blais, DM1
Hummel, J1
Di Pasquale, G1
Riva, L1
Acharjee, S1
Cannon, CP1
Delavenne, X1
Moracchini, J1
Laporte, S1
Mismetti, P1
Basset, T1
Alings, M1
Darius, H1
Kamensky, G1
Reilly, PA1
Golembiewski, JA1
Garwood, CL1
Hwang, JM1
Moser, LR1
Moser, M1
Samamaa, MM1
Conard, J1
Flaujac, C1
Combe, S1
Horellou, MH1
Redberg, RF1
Jacobs, JM1
Stessman, J1
Uchino, K1
Hernandez, AV1
Lakkireddy, D1
Reddy, YM1
Di Biase, L1
Vanga, SR1
Santangeli, P1
Swarup, V1
Pimentel, R1
Mansour, MC1
D'Avila, A1
Sanchez, JE1
Burkhardt, JD1
Chalhoub, F1
Mohanty, P1
Coffey, J1
Shaik, N1
Monir, G1
Reddy, VY1
Ruskin, J1
Natale, A1
Harenberg, J1
Giese, C1
Marx, S1
Krämer, R1
Dahl, OE1
Ahmed, S1
Levin, V1
Malacoff, R1
Martinez, MW1
Sternotte, A1
Douxfils, J1
Chatelain, B1
Chatelain, C1
Mullier, F1
Dogné, JM1
Spinewine, A1
Correia, LC1
Lopes, AA1
Little, JW1
Hughes, PJ1
Freeman, MK1
Garcia, DA1
Heidbuchle, H1
Goel, R1
Srivathsan, K1
Sinauridze, EI1
Panteleev, MA1
Ataullakhanov, FI1
Radecki, RP1
Takahashi, N1
Kaseno, K1
Naito, S1
Nakamura, K2
Sakamoto, T1
Sasaki, T1
Tsukada, N1
Hayano, M1
Nishiuchi, S1
Fuke, E1
Miki, Y1
Yamashita, E1
Kumagai, K1
Oshima, S1
Tada, H1
Momot, AP1
Grigor'ev, EV1
Tsyvkina, LP1
Panov, MIu1
Merkulov, IV1
Crockett, MT1
Moynagh, MR1
Kavanagh, EC1
Alonso-Coello, P1
Zhou, Q1
Guyatt, G1
Seiffge, D1
Nedeltchev, K1
Lyrer, P1
Travis, E1
Strang, J1
Spyropoulos, AC1
Gerotziafas, G1
Kaatz, S1
Ortel, TL2
Kirley, K1
Qato, DM1
Kornfield, R1
Stafford, RS1
Alexander, GC1
Graf, L1
Tsakiris, DA1
Naccarelli, GV1
Gonzalez, MD1
Durin, O1
Donato, G1
Nanetti, M1
Foffa, A1
Inama, G1
Valle Bernad, R1
Nagler, M1
Wuillemin, W1
Haschke, M1
Kim, JS1
She, F1
Jongnarangsin, K1
Chugh, A1
Latchamsetty, R1
Ghanbari, H1
Crawford, T1
Suwanagool, A1
Sinno, M1
Carrigan, T1
Kennedy, R1
Saint-Phard, W1
Yokokawa, M1
Good, E1
Bogun, F1
Pelosi, F1
Morady, F1
Oral, H1
Pawlikowska, Z1
Szponar, J1
Shevelev, VI1
Kanorsky, SG1
Kraglund, KL1
Husted, SE1
Modrau, B1

Clinical Trials (16)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Observational Study of the Direct Oral Anticoagulants Periprocedural Management[NCT03182218]1,100 participants (Actual)Observational2015-02-28Completed
This is a Prospective, Open-label Phase 2 Pilot Study With Independent Evaluation of All Outcomes and a Historical Control Group to Determine if Rivaroxaban (Xarelto) is Feasible and Safe for Prevention of Major Complications in Patients Undergoing a Mech[NCT02128841]Phase 212 participants (Actual)Interventional2012-09-30Terminated (stopped due to not enough patients)
A Prospective, Randomized, Active (Warfarin) Controlled, Parallel-arm Clinical Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely and Effectively on Apixaban[NCT04142658]Phase 3863 participants (Actual)Interventional2020-05-01Terminated (stopped due to Safety)
Pharmacogenetic Algorithm of Response to Warfarin During Initial Anticoagulation in Chinese Elderly Patients[NCT02211326]660 participants (Actual)Interventional2014-09-01Completed
Evaluation of the Long Term Safety of the Use of Dabigatran Etexilate in Patients With a Bileaflet Mechanical Heart Valve[NCT01505881]Phase 2158 participants (Actual)Interventional2011-12-31Terminated
A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt[NCT01452347]Phase 2328 participants (Actual)Interventional2011-10-31Terminated
Italian Registry In the Setting of AF Ablation With Rivaroxaban[NCT04315974]250 participants (Anticipated)Observational [Patient Registry]2020-05-15Recruiting
Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (BOAT OAR)[NCT03515083]100 participants (Actual)Interventional2017-07-17Completed
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600]Phase 318,113 participants (Actual)Interventional2005-12-31Completed
Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777]4,162 participants (Actual)Observational2014-04-30Completed
Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study[NCT03181386]Phase 360 participants (Actual)Interventional2017-05-03Completed
Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants[NCT02185027]1,166 participants (Actual)Observational2013-06-30Completed
Correlation Between Bleeding Complication and Treatment Failure of DOAC and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04597593]200 participants (Actual)Observational2020-10-07Completed
Investigation of Genetic Variations on Patients With Adverse Events While on Direct Oral Anticoagulants (DOACs)[NCT04580589]210 participants (Actual)Observational2021-02-01Completed
Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445]Phase 4160 participants (Actual)Interventional2019-05-01Completed
Investigation of Genetic Variations on Patients With Adverse Drug Events While on Direct Oral Anticoagulants (DOACs)[NCT04247919]3 participants (Actual)Observational2020-01-10Terminated (stopped due to Limitations to recruitment due to COVID-19)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Patients With AEs Leading to Discontinuation of Trial Drug

"Percentage of patients with Adverse Events leading to discontinuation of trial drug.~Prespecified clinical outcome events were not recorded as Adverse Events." (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)

Interventionpercentage of participants (Number)
Dabigatran Etexilate (DE)5.1
Warfarin1.7

Percentage of Patients With Any Adverse Event (AE)

Percentage of patients with Adverse Events. Prespecified clinical outcome events were not recorded as Adverse Events. (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)

Interventionpercentage of participants (Number)
Dabigatran Etexilate (DE)39.4
Warfarin37.3

Percentage of Patients With Serious AEs

Percentage of patients with Serious Adverse Events (SAE). Prespecified clinical outcome events were not recorded as Adverse Events. (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)

Interventionpercentage of participants (Number)
Dabigatran Etexilate (DE)3.0
Warfarin6.8

Percentage of Deaths, Venous Thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attacks (TIA), Strokes, Systemic Embolism, and Valve Thrombosis.

"Clinical efficacy outcome events presented are:~Death, Venous thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attack (TIA), Stroke, Systemic embolism and Valve thrombosis" (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)

,
Interventionpercentage of participants (Number)
DeathVenous thromboembolismMyocardial InfarctionTransient Ischaemic AttackStrokeSystemic embolismValve thrombosis
Dabigatran Etexilate (DE)0.00.01.01.03.00.02.0
Warfarin1.70.00.00.00.00.00.0

Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at End of Trial (EoT) at Week 12

"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~(As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients)~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 12

Interventionng/mL (Geometric Mean)
Observed108.21
Predicted104.80

Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 2

"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 2

Interventionng/mL (Geometric Mean)
Observed84.08
Predicted99.55

Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 4

"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 4

Interventionng/mL (Geometric Mean)
Observed104.43
Predicted109.36

Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations at Steady State (C Trough,ss) at Week 1

"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE) .~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 1

Interventionng/mL (Geometric Mean)
Observed73.86
Predicted99.52

Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at End of Trial (EoT) Week 12

Percentage of patients with observed Ctrough,ss value < 50 ng/mL (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 12

Interventionpercentage of participants (Number)
Patients Evaluated7.4

Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 1

Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 1

Interventionpercentage of participants (Number)
Patients Evaluated26.9

Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 2

Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 2

Interventionpercentage of participants (Number)
Patients Evaluated19.2

Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 4

Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 4

Interventionpercentage of participants (Number)
Patients Evaluated9.8

Abnormal Liver Function Test

Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months

Interventionparticipants (Number)
Dabigatran 110 mg11
Dabigatran 150 mg14
Warfarin21

Yearly Event Rate for Composite Endpoint of Stroke/SEE

Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg1.54
Dabigatran 150 mg1.11
Warfarin1.71

Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death

Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.85
Dabigatran 150 mg4.32
Warfarin5.20

Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death

Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.26
Dabigatran 150 mg3.68
Warfarin4.35

Bleeding Events (Major and Minor)

"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage) (Number)
Major bleedsMinor bleeds
Dabigatran 110 mg2.9913.16
Dabigatran 150 mg3.5514.85
Warfarin3.8116.37

Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)

Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage)] (Number)
intracerebral hemorrhageintracranial hemorrhage (ICH)
Dabigatran 110 mg0.120.23
Dabigatran 150 mg0.100.32
Warfarin0.380.76

Reviews

55 reviews available for beta-alanine and Thromboembolism

ArticleYear
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
    Hospital practice (1995), 2013, Volume: 41, Issue:1

    Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombin

2013
Perioperative management of anticoagulation in elective surgery.
    ANZ journal of surgery, 2013, Volume: 83, Issue:11

    Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Cardiovascular Di

2013
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
    Stroke, 2013, Volume: 44, Issue:6 Suppl 1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation

2013
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:24

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration S

2013
New anticoagulants as thromboprophylaxis after total hip or knee replacement.
    International journal of technology assessment in health care, 2013, Volume: 29, Issue:3

    Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benz

2013
The perioperative management of new direct oral anticoagulants: a question without answers.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:3

    Topics: Administration, Oral; Aged; Anesthesiology; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl

2013
Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
    Heart (British Cardiac Society), 2014, Volume: 100, Issue:4

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2014
Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2013, Volume: 37, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2013
Novel oral anticoagulants in non-valvular atrial fibrillation.
    Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini

2013
New oral anticoagulants after acute coronary syndrome.
    Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; C

2013
Novel oral anticoagulants in secondary prevention of stroke.
    Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabig

2013
Bleeding and antidotes in new oral anticoagulants.
    Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabig

2013
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
    Polskie Archiwum Medycyny Wewnetrznej, 2013, Volume: 123, Issue:11

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ab

2013
Advantages and limitations of the new anticoagulants.
    Journal of internal medicine, 2014, Volume: 275, Issue:1

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; D

2014
Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran.
    The American journal of cardiology, 2014, Mar-15, Volume: 113, Issue:6

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Global Health; Hemorrh

2014
Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.
    The American journal of cardiology, 2014, Apr-01, Volume: 113, Issue:7

    Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr

2014
New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
    Acta anaesthesiologica Scandinavica, 2014, Volume: 58, Issue:6

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring;

2014
Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
    The American journal of cardiology, 2014, Aug-15, Volume: 114, Issue:4

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2014
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:8

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans;

2014
Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants.
    Hospital practice (1995), 2014, Volume: 42, Issue:3

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hum

2014
Reversal agents in development for the new oral anticoagulants.
    Postgraduate medicine, 2014, Volume: 126, Issue:7

    Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Benzimidazoles; beta-Ala

2014
Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban.
    Current opinion in critical care, 2015, Volume: 21, Issue:2

    Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor Xa I

2015
Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.
    Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:4

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, R

2015
Overview of the new oral anticoagulants: opportunities and challenges.
    Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:5

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani

2015
Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
    Archives of pathology & laboratory medicine, 2015, Volume: 139, Issue:5

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation

2015
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure].
    Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:16

    Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine;

2015
[Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ].
    Zeitschrift fur Orthopadie und Unfallchirurgie, 2010, Volume: 148, Issue:5

    Topics: Administration, Oral; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morphol

2010
Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Cardiovascular therapeutics, 2010, Volume: 28, Issue:5

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; He

2010
Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Design; Humans;

2011
Atrial fibrillation: epidemiology, prognosis and therapy.
    Minerva medica, 2011, Volume: 102, Issue:3

    Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimida

2011
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Medecine sciences : M/S, 2011, Volume: 27, Issue:5

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tr

2011
New anticoagulants: how to deal with treatment failure and bleeding complications.
    British journal of clinical pharmacology, 2011, Volume: 72, Issue:4

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxab

2011
[New concepts in the therapy of atrial fibrillation].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:31-32

    Topics: Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablati

2011
[Atrial fibrillation: novel possibilities of anticoagulant therapy in patients subjected to cardioversion].
    Kardiologiia, 2011, Volume: 51, Issue:7

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Echo

2011
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].
    Giornale italiano di cardiologia (2006), 2011, Volume: 12, Issue:9

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine;

2011
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
    Critical pathways in cardiology, 2011, Volume: 10, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biopharmace

2011
Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
    Pharmacotherapy, 2011, Volume: 31, Issue:12

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International

2011
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.
    Archives of internal medicine, 2012, Mar-12, Volume: 172, Issue:5

    Topics: Acute Coronary Syndrome; Adult; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Incidence;

2012
Determination of dabigatran in human plasma samples.
    Seminars in thrombosis and hemostasis, 2012, Volume: 38, Issue:1

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Thromboembolism

2012
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.
    Vascular health and risk management, 2012, Volume: 8

    Topics: Administration, Oral; Animals; Antithrombins; Arterial Occlusive Diseases; Benzimidazoles; beta-Alan

2012
Dabigatran: a new chapter in anticoagulation.
    Cardiovascular & hematological agents in medicinal chemistry, 2012, Volume: 10, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat

2012
[Clinical studies, the interests and limits of using dabigatran in atrial fibrillation].
    Journal de pharmacie de Belgique, 2012, Issue:1

    Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-A

2012
New oral anticoagulants: will they replace warfarin?
    Oral surgery, oral medicine, oral pathology and oral radiology, 2012, Volume: 113, Issue:5

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Hypersensitivit

2012
Newer oral anticoagulant agents: a new era in medicine.
    Current cardiology reviews, 2012, Volume: 8, Issue:2

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors

2012
Anticoagulant therapy: basic principles, classic approaches and recent developments.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2012, Volume: 23, Issue:6

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Factor Xa; Factor Xa In

2012
The novel oral anticoagulants: an update for the interventional radiologist.
    AJR. American journal of roentgenology, 2012, Volume: 199, Issue:3

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; F

2012
Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:4

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].
    Therapeutische Umschau. Revue therapeutique, 2012, Volume: 69, Issue:9

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:4

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Pr

2012
Anticoagulant treatment: the end of the old agents?
    Swiss medical weekly, 2012, Volume: 142

    Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dr

2012
[Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests].
    Therapeutische Umschau. Revue therapeutique, 2012, Volume: 69, Issue:11

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagula

2012
[Clinical pharmacological aspects of new oral anticoagulants].
    Therapeutische Umschau. Revue therapeutique, 2012, Volume: 69, Issue:11

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP3A; Cytochro

2012
Perioperative management of patients on chronic antithrombotic therapy.
    Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012

    Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic A

2012
[New anticoagulants--are we prepared?].
    Przeglad lekarski, 2012, Volume: 69, Issue:8

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans;

2012
[Anticoagulant therapy in stroke patients].
    Ugeskrift for laeger, 2013, Jan-28, Volume: 175, Issue:5

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral He

2013

Trials

7 trials available for beta-alanine and Thromboembolism

ArticleYear
Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2013, Volume: 37, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Catheter Ablation; Comorb

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Warfarin or dabigatran for treatment of atrial fibrillation.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:7

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Europe; Hemorrh

2014
[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2014, Volume: 37, Issue:221

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibi

2014
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
    Annals of internal medicine, 2011, Nov-15, Volume: 155, Issue:10

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2011
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I

2012
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I

2012
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I

2012
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I

2012
Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:10

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Abl

2012

Other Studies

82 other studies available for beta-alanine and Thromboembolism

ArticleYear
[Extensive thromboembolism after cardioversion in a patient treated with dabigatran].
    Ugeskrift for laeger, 2013, Feb-04, Volume: 175, Issue:6

    Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Electric Counter

2013
Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial".
    Circulation, 2013, Mar-19, Volume: 127, Issue:11

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Thromboembolism; War

2013
Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".
    Circulation, 2013, Mar-19, Volume: 127, Issue:11

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Thromboembolism; War

2013
Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.
    Circulation. Arrhythmia and electrophysiology, 2013, Volume: 6, Issue:3

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confidence Intervals; Dabig

2013
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
    MMW Fortschritte der Medizin, 2013, Feb-21, Volume: 155, Issue:3

    Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel;

2013
Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2013, Volume: 37, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2013
New approaches to reversing oral anticoagulant therapy. Introduction.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, May-15, Volume: 70, Issue:10 Suppl 1

    Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-A

2013
Pharmacologic interventions for reversing the effects of oral anticoagulants.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, May-15, Volume: 70, Issue:10 Suppl 1

    Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-A

2013
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.
    Circulation, 2013, Mar-19, Volume: 127, Issue:11

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Thromboembolism; War

2013
Perioperative management of patients who are receiving a novel oral anticoagulant.
    Internal and emergency medicine, 2013, Volume: 8, Issue:6

    Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Perioperat

2013
Fatal association of mechanical valve thrombosis with dabigatran: a report of two cases.
    Chest, 2013, Volume: 144, Issue:1

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; F

2013
Periprocedural dabigatran anticoagulation for atrial fibrillation ablation: do we have enough information to make a rational decision.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2013, Volume: 37, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2013
Letter by May et al regarding article, "Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation" by Bassiouny et al.
    Circulation. Arrhythmia and electrophysiology, 2013, Volume: 6, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Thromboembo

2013
Response to Letter by May et al regarding article, "Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation" by Bassiouny et al.
    Circulation. Arrhythmia and electrophysiology, 2013, Volume: 6, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Thromboembo

2013
Dabigatran and mechanical heart valves--not as easy as we hoped.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Valve P

2013
Anticoagulation therapy: Results of RE-ALIGN disappoint.
    Nature reviews. Cardiology, 2013, Volume: 10, Issue:11

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2013
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead.
    Heart (British Cardiac Society), 2014, Volume: 100, Issue:4

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperati

2014
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
    Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; D

2014
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead. The authors' reply.
    Heart (British Cardiac Society), 2014, Volume: 100, Issue:4

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperati

2014
ACP Journal Club. Dabigatran increased bleeding and stroke compared with warfarin after mechanical heart valve implantation.
    Annals of internal medicine, 2013, Dec-17, Volume: 159, Issue:12

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2013
Dabigatran use in mechanical heart valve patients.
    Future cardiology, 2014, Volume: 10, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Dabigatran versus warfarin in patients with mechanical heart valves: comment.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Dabigatran versus warfarin in patients with mechanical heart valves: reply.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Dabigatran in patients with mechanical heart valves.
    The New England journal of medicine, 2014, 01-23, Volume: 370, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Dabigatran in patients with mechanical heart valves.
    The New England journal of medicine, 2014, 01-23, Volume: 370, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Dabigatran in patients with mechanical heart valves.
    The New England journal of medicine, 2014, 01-23, Volume: 370, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Dabigatran in patients with mechanical heart valves.
    The New England journal of medicine, 2014, 01-23, Volume: 370, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Dabigatran in patients with mechanical heart valves.
    The New England journal of medicine, 2014, 01-23, Volume: 370, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Dabigatran in patients with mechanical heart valves.
    The New England journal of medicine, 2014, 01-23, Volume: 370, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Novel anticoagulants in patients with mechanical heart valves.
    Evidence-based medicine, 2014, Volume: 19, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2014
[Extrapolation of physiopathological data to clinical practice: Example of dabigatran in off-label use].
    Presse medicale (Paris, France : 1983), 2014, Volume: 43, Issue:4 Pt 1

    Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Contraindications; Dabigatr

2014
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:8

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cathe

2014
Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits.
    Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1

    Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Catheter Obstruction; Catheters; Dabigatran; D

2014
Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
    The American journal of cardiology, 2014, Apr-15, Volume: 113, Issue:8

    Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benz

2014
Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 40, Issue:1

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Abl

2014
ACP Journal Club. Review: Dabigatran does not differ from vitamin K antagonists for mortality or major bleeding.
    Annals of internal medicine, 2014, Apr-15, Volume: 160, Issue:8

    Topics: Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Thromboembo

2014
[Not Available].
    Praxis, 2014, May-07, Volume: 103, Issue:10

    Topics: Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Thromboembo

2014
Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
    Seminars in hematology, 2014, Volume: 51, Issue:2

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; D

2014
Dabigatran in catheter ablation of atrial fibrillation: a call for a randomized control trial.
    The American journal of cardiology, 2014, Jun-15, Volume: 113, Issue:12

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Humans; Ischemic Attack, Trans

2014
[Dabigatran versus warfarin in patients with mechanical heart valves].
    Revista clinica espanola, 2014, Volume: 214, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Myocardial infarction complicated by left ventricular thrombus and fatal thromboembolism following abrupt cessation of dabigatran.
    BMJ case reports, 2014, Jul-04, Volume: 2014

    Topics: Aged, 80 and over; Angiography; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outco

2014
Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.
    The American journal of cardiology, 2014, Sep-15, Volume: 114, Issue:6

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabig

2014
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:10

    Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles

2014
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:5

    Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction;

2014
[New oral anticoagulants are as safe in elderly patients as conventional drugs].
    Praxis, 2014, Aug-20, Volume: 103, Issue:17

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; H

2014
A retrospective descriptive analysis of patient adherence to dabigatran at a large academic medical center.
    Journal of managed care & specialty pharmacy, 2014, Volume: 20, Issue:10

    Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanin

2014
Effects of thromboembolism prophylaxis with dabigatran on perioperative blood loss and wound secretion in primary hip arthroplasty.
    Technology and health care : official journal of the European Society for Engineering and Medicine, 2014, Volume: 22, Issue:6

    Topics: Aged; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Body Fluids; Dabi

2014
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
    BMC family practice, 2014, Oct-25, Volume: 15

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2014
RE-CIRCUIT study-randomized evaluation of Dabigatran etexilate compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation strategy.
    The American journal of cardiology, 2015, Jan-01, Volume: 115, Issue:1

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Humans; Ischemic Attack, Trans

2015
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
    Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2014, Volume: 20, Issue:4

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coa

2014
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
    The American journal of gastroenterology, 2015, Volume: 110, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; E

2015
[Extended options of anticoagulant treatment in thromboembolism].
    Vnitrni lekarstvi, 2014, Volume: 60, Issue:11

    Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Czech Republic; Dabigatran;

2014
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
    MMW Fortschritte der Medizin, 2015, Jan-19, Volume: 157, Issue:1

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-L

2015
[Periprocedural management of anticoagulation in patients undergoing atrial fibrillation ablation].
    Revue medicale suisse, 2015, Mar-04, Volume: 11, Issue:464

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Hu

2015
Perioperative Management of Dabigatran: A Prospective Cohort Study.
    Circulation, 2015, Jul-21, Volume: 132, Issue:3

    Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Di

2015
Dabigatran in atrial fibrillation: pharmacology and clinical trials.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2011, Volume: 32, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat

2011
A new era for anticoagulation in atrial fibrillation.
    The New England journal of medicine, 2011, Sep-15, Volume: 365, Issue:11

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines;

2011
Drug-induced exanthem following dabigatran.
    The Annals of pharmacotherapy, 2011, Volume: 45, Issue:10

    Topics: Adult; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Hypersensi

2011
The use of dabigatran immediately after atrial fibrillation ablation.
    Journal of cardiovascular electrophysiology, 2012, Volume: 23, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2012
UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma.
    Journal of pharmaceutical and biomedical analysis, 2012, Jan-25, Volume: 58

    Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Chromatography, Liquid; Chromatography, Reverse-P

2012
Dabigatran: a new oral anticoagulant.
    Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses, 2011, Volume: 26, Issue:6

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Thro

2011
[Anticoagulation in atrial fibrillation: a new era has begun].
    Hamostaseologie, 2012, Volume: 32, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines;

2012
[Pharmacologic heterogeneity of new anticoagulants].
    Journal des maladies vasculaires, 2011, Volume: 36 Suppl 1

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet

2011
Important data after drug approval: comment on "Dabigatran association with higher risk of acute coronary events".
    Archives of internal medicine, 2012, Mar-12, Volume: 172, Issue:5

    Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Myocardial

2012
Dabigatran: do we have sufficient data?: comment on "Dabigatran association with higher risk of acute coronary events".
    Archives of internal medicine, 2012, Mar-12, Volume: 172, Issue:5

    Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Myocardial

2012
Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
    Journal of the American College of Cardiology, 2012, Mar-27, Volume: 59, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr

2012
Anticoagulation therapy. Dabigatran and risk of myocardial infarction.
    Nature reviews. Cardiology, 2012, Mar-13, Volume: 9, Issue:5

    Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Female; Humans; Male; Myocardial Infarction;

2012
Dabigatran and myocardial infarction: meta-illusion?
    Archives of internal medicine, 2012, May-28, Volume: 172, Issue:10

    Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Female; Humans; Male; Myocardial Infarction;

2012
[Expanded arsenal in atrial fibrillation: bye-bye marcumar?].
    MMW Fortschritte der Medizin, 2012, Jan-19, Volume: 154, Issue:1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug A

2012
Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2012, Volume: 27, Issue:6

    Topics: Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Fibrinolyt

2012
Anticoagulation, novel agents, and procedures: can we pardon the interruption?
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Thromboe

2012
Dabigatran: uncharted waters and potential harms.
    Annals of internal medicine, 2012, Jul-03, Volume: 157, Issue:1

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemor

2012
Can dabigatran be an alternative periprocedural anticoagulation for atrial fibrillation ablation?
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:10

    Topics: Antithrombins; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Humans; Male; Pe

2012
[The monitoring of application of dabigatran as a remedy of prevention of thromboembolic complications after hip joint arthroplasty].
    Klinicheskaia laboratornaia diagnostika, 2012, Issue:5

    Topics: Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrin Fibrinogen

2012
Perioperative management of dabigatran: the Nelson experience to date.
    The New Zealand medical journal, 2012, Aug-24, Volume: 125, Issue:1360

    Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Middle Age

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2013, Volume: 36, Issue:1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2013
[Antithrombotic prevention in atrial fibrillation: the new anticoagulant drugs].
    Giornale italiano di cardiologia (2006), 2012, Volume: 13, Issue:10 Suppl 2

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans

2012
[Introduction].
    Revista clinica espanola, 2012, Volume: 212 Suppl 1

    Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans

2012
Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.
    Heart rhythm, 2013, Volume: 10, Issue:4

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Case-Control Studies; Cathe

2013
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
    Klinicheskaia meditsina, 2012, Volume: 90, Issue:10

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz

2012